Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Jørgensen, Heather G and Allan, Elaine K and Mountford, Joanne C and Richmond, Linda and Harrison, Simon and Elliott, Moira A and Holyoake, Tessa L (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-6. ISSN 0301-472X

Full text not available in this repository.Request a copy from the Strathclyde author

Official URL: https://doi.org/10.1016/j.exphem.2005.05.020

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

ORCID iDs

Jørgensen, Heather G, Allan, Elaine K, Mountford, Joanne C, Richmond, Linda, Harrison, Simon, Elliott, Moira A

and Holyoake, Tessa L;

Citations and altmetrics

Item metadata

Item type:	Article
ID code:	32632
Dates:	Date Event 2005 Published
Keywords:	antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines, Therapeutics. Pharmacology, Neoplasms. Tumors. Oncology (including Cancer), Cell Biology, Genetics, Molecular Biology, Hematology, Cancer Research
Subjects:	Medicine > Therapeutics. Pharmacology Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer)
Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Depositing user:	Pure Administrator
Date deposited:	19 Aug 2011 20:05
Last modified:	20 Jan 2021 19:29
URI:	https://strathprints.strath.ac.uk/id/eprint/32632

Export

CORE (COnnecting REpositories)